Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc.

January 31, 2008 09:19 ET

Critical Outcome Technologies Inc. Will Present Data Package for COTI-2 at BioPartnering North America

LONDON, ONTARIO--(Marketwire - Jan. 31, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced today that the Company will present the data package for its lead oncology compound COTI-2 at BioPartnering North America (BPNA) taking place February 3-5, 2008 in Vancouver, BC.

Critical Outcome Technologies Inc. (COTI) has arranged meetings at BPNA with executives from several major pharmaceutical organizations. The primary objective of the meetings is to present the COTI-2 data package and to explore collaboration opportunities regarding its ongoing development. COTI also plans to discuss with prospective partners opportunities to leverage its proprietary technology, CHEMSAS®, to accelerate the identification of high potential drug candidates for therapy areas of partner interest. COTI will be represented by Dr. Wayne Danter, President and Chief Scientific Officer and Michael Barr, Director of Business Development and Marketing.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

Contact Information